FDA: BioDelivery Sciences Should Improve “Safe Use” REMS Provisions For Oral Fentanyl Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Onsolis “complete response” letter is “as close to approval as one can get without having it,” BDSI CEO says.